Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

[Rivaroxaban in the prevention and treatment of thromboembolic disorders].

Helbing T, Bode C, Moser M.

Hamostaseologie. 2012;32(3):195-202. doi: 10.5482/HAMO-12-05-0005. Epub 2012 Jul 10. German.

PMID:
22777255
2.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
3.

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

Cohen AT, Dobromirski M.

Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Review.

PMID:
22371186
4.
6.

Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.

Biemond BJ, Perzborn E, Friederich PW, Levi M, Buetehorn U, Büller HR.

Thromb Haemost. 2007 Mar;97(3):471-7.

PMID:
17334516
7.

Rivaroxaban: new drug. After hip or knee replacement surgery: LMWH is safer.

[No authors listed]

Prescrire Int. 2009 Aug;18(102):151-3.

PMID:
19743567
8.

Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Turpie AG, Kreutz R, Llau J, Norrving B, Haas S.

Thromb Haemost. 2012 Nov;108(5):876-86. doi: 10.1160/TH12-03-0209. Epub 2012 Sep 26. Review.

PMID:
23014816
9.

Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Becker RC, Nessel CC, Berkowitz SD, Califf RM, Fox KA, Mahaffey KW.

J Am Coll Cardiol. 2013 Feb 12;61(6):651-8. doi: 10.1016/j.jacc.2012.09.057.

10.

Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Abrams PJ, Emerson CR.

Pharmacotherapy. 2009 Feb;29(2):167-81. doi: 10.1592/phco.29.2.167. Review.

PMID:
19170587
11.

Rivaroxaban, an oral direct factor Xa inhibitor.

Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM.

Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . Review.

PMID:
18491993
12.

[Rivaroxaban (Xarelto): efficacy and safety].

Rosencher N, Arnaout L, Chabbouh T, Bellamy L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7. doi: 10.1016/S0750-7658(08)75143-8. Review. French.

PMID:
19185784
13.

[Rivaroxaban: mode of action].

Drouet L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S9-15. doi: 10.1016/S0750-7658(08)75141-4. Review. French.

PMID:
19185786
14.

Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Laux V, Perzborn E, Kubitza D, Misselwitz F.

Semin Thromb Hemost. 2007 Jul;33(5):515-23. Review.

PMID:
17629849
15.

Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.

Morell J, Sullivan B, Khalabuda M, McBride BF.

J Clin Pharmacol. 2010 Sep;50(9):986-1000. doi: 10.1177/0091270009355814. Epub 2010 Feb 2.

PMID:
20124518
16.

Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism.

Chen T, Lam S.

Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. Review.

PMID:
19525681
17.

[New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

Dumont B, Faille D, Ajzenberg N.

Med Sci (Paris). 2011 May;27(5):493-500. doi: 10.1051/medsci/2011275014. Epub 2011 May 25. Review. French.

18.

Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.

Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators.

Circulation. 2007 Jul 10;116(2):180-7. Epub 2007 Jun 18.

19.

A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.

Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators.

Circulation. 2006 Nov 28;114(22):2374-81. Epub 2006 Nov 20.

20.

Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.

Parry TJ, Huang Z, Chen C, Connelly MA, Perzborn E, Andrade-Gordon P, Damiano BP.

Blood Coagul Fibrinolysis. 2011 Dec;22(8):720-6. doi: 10.1097/MBC.0b013e32834cb30e.

PMID:
21986468

Supplemental Content

Support Center